X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3254) 3254
Publication (304) 304
Book Review (170) 170
Conference Proceeding (4) 4
Book Chapter (2) 2
Dissertation (1) 1
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3046) 3046
aminopyridines - pharmacology (2399) 2399
animals (2287) 2287
humans (1253) 1253
male (1199) 1199
rats (918) 918
4-aminopyridine (686) 686
female (684) 684
pharmacology & pharmacy (659) 659
mice (623) 623
in vitro techniques (508) 508
dose-response relationship, drug (424) 424
aminopyridines - therapeutic use (348) 348
neurosciences (334) 334
aminopyridines - chemistry (314) 314
action potentials - drug effects (252) 252
aminopyridines - administration & dosage (247) 247
cell line, tumor (243) 243
tetraethylammonium compounds - pharmacology (243) 243
chemistry, medicinal (237) 237
rats, sprague-dawley (236) 236
aminopyridines (223) 223
biochemistry & molecular biology (220) 220
oncology (208) 208
time factors (208) 208
benzamides - pharmacology (207) 207
rats, inbred strains (207) 207
membrane potentials - drug effects (205) 205
guinea pigs (203) 203
indoles - pharmacology (197) 197
structure-activity relationship (196) 196
adult (193) 193
article (185) 185
aminopyridines - chemical synthesis (181) 181
middle aged (175) 175
aminopyridines - pharmacokinetics (174) 174
cancer (174) 174
piperazines - pharmacology (174) 174
amrinone (167) 167
disease models, animal (164) 164
tetraethylammonium (164) 164
kinetics (163) 163
aminopyridines - metabolism (162) 162
research (161) 161
cells, cultured (159) 159
calcium - metabolism (157) 157
antineoplastic agents - pharmacology (154) 154
electric stimulation (154) 154
cell proliferation - drug effects (151) 151
mutation (149) 149
aminopyridines - adverse effects (148) 148
cyclopropanes - pharmacology (147) 147
administration, oral (145) 145
pyridines - pharmacology (144) 144
in-vitro (143) 143
phosphorylation (143) 143
potassium - metabolism (142) 142
protein kinase inhibitors - pharmacology (142) 142
expression (140) 140
ion channels - drug effects (136) 136
roflumilast (136) 136
serotonin antagonists - pharmacology (136) 136
analysis (134) 134
cell line (134) 134
rats, wistar (134) 134
4-aminopyridine - pharmacology (132) 132
dogs (130) 130
mice, inbred c57bl (130) 130
physiology (130) 130
cell biology (128) 128
aged (123) 123
signal transduction - drug effects (123) 123
apoptosis - drug effects (122) 122
activation (121) 121
rat (120) 120
abridged index medicus (118) 118
apoptosis (118) 118
muscle contraction - drug effects (118) 118
calcium - pharmacology (117) 117
synaptic transmission - drug effects (117) 117
models, molecular (114) 114
benzamides - therapeutic use (112) 112
kinases (111) 111
cells (110) 110
drug interactions (110) 110
morpholines - pharmacology (110) 110
rabbits (109) 109
pharmacology (108) 108
inflammation (106) 106
neurons - drug effects (105) 105
cardiotonic agents - pharmacology (103) 103
obstructive pulmonary-disease (103) 103
xenograft model antitumor assays (103) 103
myocardial contraction - drug effects (102) 102
4-aminopyridine - analogs & derivatives (101) 101
electrophysiology (101) 101
inhibitors (101) 101
tetrodotoxin - pharmacology (101) 101
molecular structure (99) 99
drug synergism (97) 97
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3120) 3120
German (44) 44
Japanese (25) 25
Russian (24) 24
Chinese (17) 17
French (10) 10
Italian (6) 6
Spanish (6) 6
Lithuanian (2) 2
Bulgarian (1) 1
Czech (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, ISSN 0012-1797, 04/2017, Volume 66, Issue 4, p. 1062
Journal Article
Nature Communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, pp. 5712 - 5712
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway... 
BRAF INHIBITION | TYROSINE KINASE AXL | RAF INHIBITION | CELLS | BREAST-CANCER METASTASIS | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | MEK INHIBITORS | UP-REGULATION | CONFERS RESISTANCE | Prognosis | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - metabolism | Signal Transduction | Proto-Oncogene Proteins - genetics | Imidazoles - pharmacology | Melanoma - pathology | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aminopyridines - pharmacology | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Oximes - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Microphthalmia-Associated Transcription Factor - genetics | Pyridones - pharmacology | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 2004 - 2013
Background & Aims: Chemotherapy with an anticancer agent generally causes gastrointestinal tract disorders such as vomiting and anorexia, but the mechanism... 
Gastroenterology and Hepatology | SEROTONIN RECEPTOR | GHRELIN LEVELS | SYMPTOMS | MICE | EMESIS | GASTROENTEROLOGY & HEPATOLOGY | STOMACH | Receptor, Serotonin, 5-HT2B - metabolism | Receptor, Serotonin, 5-HT2C - metabolism | Body Weight - drug effects | Drugs, Chinese Herbal - pharmacology | Male | Stomach - metabolism | Drugs, Chinese Herbal - metabolism | Anorexia - physiopathology | Quinolines - pharmacology | Serotonin Receptor Agonists - pharmacology | Dose-Response Relationship, Drug | Serotonin 5-HT2 Receptor Antagonists | Chalcones - pharmacology | Dopamine Antagonists - metabolism | Receptors, Ghrelin - metabolism | Indoles - pharmacology | Stomach - innervation | Stomach - drug effects | Drugs, Chinese Herbal - therapeutic use | Flavones - pharmacology | Acylation | Disease Models, Animal | Antineoplastic Agents | Rats | Thiophenes - pharmacology | Anorexia - metabolism | Dopamine Antagonists - therapeutic use | Receptors, Ghrelin - drug effects | Piperazines - pharmacology | Rats, Sprague-Dawley | Vagotomy | Cisplatin | Ghrelin - metabolism | Eating - drug effects | Gastrointestinal Agents - pharmacology | Ghrelin - blood | Animals | Dopamine Antagonists - pharmacology | Aminopyridines - pharmacology | Serotonin - metabolism | Gastrointestinal Agents - therapeutic use | Anorexia - prevention & control | Hesperidin - pharmacology | Protein Binding | Anorexia - chemically induced | Oligopeptides - pharmacology | Gastrointestinal Agents - metabolism | Medicine, Botanic | Medicine, Herbal | Index Medicus | Abridged Index Medicus
Journal Article
Psychopharmacology, ISSN 0033-3158, 12/2008, Volume 201, Issue 3, pp. 443 - 458
Fluoxetine has relatively high affinity for Gq/11 protein-coupled 5-HT2 receptors. Part of these receptors in brain are on astrocytes, where fluoxetine causes... 
Neurosciences | Biomedicine | Serotonin | Astrocytes | Fluoxetine | EGFR transactivation | fosB | c-fos | Pharmacology/Toxicology | Psychiatry | ERK | 5-HT 2B receptor | receptor | C-fos | FosB | 5-HT | SIGNALING PATHWAYS | PSYCHIATRY | TYROSINE KINASE | PHARMACOLOGICAL CHARACTERIZATION | CELL-PROLIFERATION | 5-HT2B receptor | NEUROSCIENCES | SEROTONIN REUPTAKE INHIBITORS | MESSENGER-RNA | TISSUE DISTRIBUTION | MECHANICAL-STRESS | CULTURED ASTROCYTES | PHARMACOLOGY & PHARMACY | R-FLUOXETINE | Receptor, Epidermal Growth Factor - genetics | Up-Regulation | Phosphorylation | Transcriptional Activation - genetics | Nitriles - pharmacology | Calcium - metabolism | Maleimides - pharmacology | Substrate Specificity | Extracellular Signal-Regulated MAP Kinases - metabolism | Quinazolines | Calcium - chemistry | Receptor, Serotonin, 5-HT2B - physiology | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Receptor, Epidermal Growth Factor - metabolism | Piperidines - pharmacology | Receptor, Serotonin, 5-HT2B - drug effects | Urea - analogs & derivatives | Egtazic Acid - analogs & derivatives | Indoles - pharmacology | Proto-Oncogene Proteins c-fos - antagonists & inhibitors | Astrocytes - drug effects | Fluoxetine - pharmacology | Butadienes - pharmacology | Gene Expression | Signal Transduction | Dipeptides - pharmacology | RNA, Messenger - genetics | Cells, Cultured | Proto-Oncogene Proteins c-fos - metabolism | Antidepressive Agents, Second-Generation - pharmacology | Protein Kinase C - antagonists & inhibitors | Tyrphostins - pharmacology | Chelating Agents - pharmacology | Antidepressive Agents, Second-Generation - antagonists & inhibitors | Fluoxetine - antagonists & inhibitors | Astrocytes - physiology | Animals | Egtazic Acid - pharmacology | Aminopyridines - pharmacology | Proto-Oncogene Proteins c-fos - genetics | Mice | Urea - pharmacology | Brain | Neurotransmitters | Antidepressants | Psychopharmacology | Cells | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 825 - 837
The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is... 
Medicine & Public Health | Cell cycle | Oncology | In vivo antitumor activity | Pharmacology/Toxicology | Combination therapy | LY2835219 | Kinase inhibitor | CDK4/6 inhibitor | Cdk4/6 inhibitor | LUNG | HUMAN BREAST | PHOSPHORYLATION | CANCER | DEPENDENT KINASE 4/6 | CONSTITUTIVELY ACTIVATED FLT3 | ONCOLOGY | BRAIN METASTASES | RESTRICTION POINT | TUMOR-SUPPRESSOR | PHARMACOLOGY & PHARMACY | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Neoplasms - metabolism | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Deoxycytidine - therapeutic use | Aminopyridines - therapeutic use | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Retinoblastoma Protein - metabolism | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Retinoblastoma Protein - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Dosage and administration | Research | Gemcitabine | Studies | Protein expression | Inhibitor drugs | Kinases | Cancer therapies | Analysis | Index Medicus | CDK4 | Preclinical Studies | 6 inhibitor
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2013, Volume 71, Issue 5, pp. 1297 - 1307
To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K... 
Resistance | Angiogenesis | Medicine & Public Health | VEGFr tyrosine kinase inhibitor | Kidney cancer | mTOR inhibitor | Oncology | Cancer Research | Pharmacology/Toxicology | MAMMALIAN TARGET | RAPAMYCIN | EVEROLIMUS | GUIDELINES | NVP-BEZ235 | CANCER | TRIAL | INTERFERON-ALPHA | ONCOLOGY | TEMSIROLIMUS | mTOR inhibitor Resistance | PHARMACOLOGY & PHARMACY | PHASE-I | Niacinamide - analogs & derivatives | Humans | Imidazoles - administration & dosage | Drug Resistance, Neoplasm | Antineoplastic Agents - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - administration & dosage | Quinolines - pharmacology | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Sunitinib | Carcinoma, Hepatocellular - drug therapy | Indoles - pharmacology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Aminopyridines - administration & dosage | Sirolimus - analogs & derivatives | Carcinoma, Renal Cell - pathology | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Liver Neoplasms - drug therapy | Morpholines - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Imidazoles - pharmacology | Pyrimidines - pharmacology | Sirolimus - pharmacology | Sirolimus - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrroles - pharmacology | Signal Transduction - drug effects | Aminopyridines - pharmacology | Sorafenib | Carcinoma, Hepatocellular - pathology | Cell Line, Tumor | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Kidney Neoplasms - drug therapy | Antimitotic agents | Benchmarks | Carcinoma, Renal cell | Antineoplastic agents | Vascular endothelial growth factor | Analysis | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2011, Volume 55, Issue 10, pp. 4652 - 4658
Journal Article
Diabetes, ISSN 0012-1797, 04/2017, Volume 66, Issue 4, pp. 1062 - 1073
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 1373 - 14
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance.... 
Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Cyclin D1 - metabolism | Receptors, Estrogen - metabolism | Circulating Tumor DNA - genetics | Humans | Purines - administration & dosage | Fulvestrant - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Quinolines - pharmacology | Breast Neoplasms - metabolism | Quinoxalines - pharmacology | MCF-7 Cells | Fulvestrant - administration & dosage | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyrazoles - pharmacology | Aminopyridines - administration & dosage | Antineoplastic Agents, Hormonal - pharmacology | Signal Transduction | Purines - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Proportional Hazards Models | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Naphthalenes - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aminopyridines - pharmacology | Progression-Free Survival | High-Throughput Nucleotide Sequencing | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Mutation | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Drug Resistance, Neoplasm - drug effects | Tyrosine | Xenotransplantation | Clinical trials | Antagonists | Breast cancer | Drug resistance | Patients | Cyclin-dependent kinase 4 | Fulvestrant | Gene sequencing | Amplification | Next-generation sequencing | Inhibitors | Xenografts | Breast | Open reading frames | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Fibroblast growth factor receptors | Index Medicus
Journal Article
Journal of Anaesthesiology Clinical Pharmacology, ISSN 0970-9185, 04/2012, Volume 28, Issue 2, pp. 172 - 177
Flupirtine is neither an opioid nor a non steroidal anti-inflammatory drug (NSAID) producing its analgesic action through blockade of glutamate... 
N-methyl-D-aspartate receptor | Flupirtine | non-steroidal anti-inflammatory drug | opioids | Clinical pharmacology | Aminopyridines | Care and treatment | Pain | Research | Properties | Clinical Pharmacology
Journal Article
Psychopharmacology, ISSN 0033-3158, 9/2015, Volume 232, Issue 17, pp. 3249 - 3258
Journal Article